- CureVac, GSK load into starting block in omicron booster race
- Setback at Lundbeck: CGRP migraine drug Vyepti hits expansion snag, but sales still doubled
- Health systems increase executives' base pay, incentives in a competitive market
- NIH-backed research turns out same-day, point-of-care abnormal fetal chromosome test
- China's Jemincare nabs $650M biobucks pact with Roche's Genentech for prostate cancer hopeful
- CVS, Walmart and Walgreens ordered to pay $650M in Ohio opioid suit, but some providers worry about aftermath
- In damage control mode, Perrigo clarifies that it's off the hook in key Zantac case
- Back to basics: High-tech blood pressure monitors don't outperform standard cuffs, study finds
- Bayer parts ways with Exscientia, leaving one target in AI drug hunter's hands
- National Resilience, hot off $625M raise, bolsters Rolodex with Mayo Clinic biomanufacturing tie-up
- CDC plans overhaul to public health efforts in response to monkeypox, COVID-19 criticism
- Curis gets FDA green light to restart lymphoma trial, though partial hold on leukemia study stays in place
Featured Story | By Annalee Armstrong With competitors laps ahead on the track, CureVac and GSK are loading into the starting block for the COVID-19 booster race. The companies announced Thursday morning that a phase 1 trial for their mRNA booster vaccine targeting the omicron variant is getting underway. read more |
| |
|---|
|
Top Stories By Angus Liu Amid growing competition within the CGRP inhibitor class of migraine drugs, Lundbeck’s Vyepti has hit a setback with an "aggressive trial" as part of its market expansion plan. read more By Annie Burky Health systems are boosting executives' base salaries and incentives to attract more talent in an increasingly competitive market. Healthcare executives saw a 4.5% increase in median base salaries in 2021, according to the independent consulting firm SullivanCotter. read more By Andrea Park Not only does the new prenatal screening test backed by the National Institutes of Health return results within a single day, but it’s also just as accurate as its slower-moving counterparts, according to a study published Thursday in the New England Journal of Medicine. read more By Ben Adams After penning a deal with Orion back in May, Jemincare is back at the licensing deal table, inking a development and sales deal with Roche’s Genentech unit that is on the lookout for a new prostate cancer drug after the recent flop of its phase 3 asset ipatasertib. read more By Anastassia Gliadkovskaya Though the latest judgment is expected to set a precedent for other communities trying to hold pharmacies accountable, some providers worry about the unintended consequences of potential new dispensary restrictions. read more By Kevin Dunleavy With its stock price in free fall over fears of upcoming litigation related to Zantac, it’s damage control time for pharma giants GSK, Boehringer Ingelheim, Sanofi and Pfizer as well as a host of generic drugmakers that marketed the heartburn medicine. read more By Andrea Park In a rare exception to the usual rules of technological advancement, a new study published this week in JAMA Internal Medicine has found that high-tech bells and whistles haven’t contributed to any major improvement in clinical outcomes for at-home blood pressure monitors. read more By Annalee Armstrong Bayer and Exscientia are parting ways on an artificial intelligence collaboration that saw the pair work together to find cardiovascular and oncology targets. Exscientia revealed the end of the collaboration in a second-quarter earnings report issued after-market Wednesday. The U.K.-based AI company will retain the option to develop one of the two targets that were being worked on. read more By Fraiser Kansteiner National Resilience is teaming up on biomanufacturing with Mayo Clinic to crank out new drugs for complex and rare diseases. The partners will home in specifically on biologics derived from sources like cells, blood, enzymes, tissues, genes or genetically engineered cells. read more By Robert King CDC announced an overhaul to agency operations to better respond to public health emergencies, including reexamining the communications efforts and eliminating conflicting guidance. read more By Gabrielle Masson The FDA has greenlit Curis' phase 1/2 lymphoma trial, lifting a partial clinical hold on the study assessing emavusertib. Yet, a partial hold remains for the biotech’s leukemia trial evaluating the same drug. read more Resources Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 
